BioCentury
ARTICLE | Clinical News

NantKwest begins Phase I of NK cell therapy for solid tumors

October 27, 2017 9:43 PM UTC

NantKwest Inc. (NASDAQ:NK) began the 2-part Phase I QUILT-3.028 trial of its haNK cell therapy to treat metastatic or locally advanced solid tumors. The first part of the 16-patient trial will evaluate weekly infusions of 2x109 and 4x109 cells followed by a dose-expansion second part. The open-label, U.S. trial's primary endpoints are maximum tolerated dose (MTD), dose-limiting toxicities (DLTs) and safety. Secondary endpoints include objective response rate (ORR), progression-free survival (PFS) and overall survival (OS)...

BCIQ Company Profiles

NantKwest Inc.